American Express Announces Plans to Expand Centurion® Lounges in Two Major U.S. Airports and Prepares to Welcome Travelers with New Health and Safety Practices
Today, American Express (NYSE: AXP) announced plans to expand two of its signature Centurion Lounges and introduced The Centurion Lounge Commitment, a set of new health and safety protocols and practices, which will be implemented in all Centurion Lounges as they reopen (some starting in early October). The Centurion Lounge at New York's LaGuardia Airport (LGA) will relocate to a larger location in the brand new Terminal B, and as previously announced, the current Centurion Lounge at Las Vegas’ McCarran International Airport (LAS), will be expanded and redesigned.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200916005291/en/
Rendering of Centurion Lounge at New York's LaGuardia Airport (Photo: Business Wire)
“The health, safety and comfort of our Card Members and colleagues remains our top priority as we look to expand and reopen our iconic Centurion Lounges around the world,” said Alexander Lee, Vice President Travel Experiences & Benefits. “We believe travel is core to our Card Members’ lifestyles, and like them, we look forward to the day when we can travel the world again - we’re excited to welcome them back into our Centurion Lounges soon.”
Upgrading the Centurion Lounge Experience at LAS and LGA:
Renovations to The Centurion Lounges at New York's LaGuardia Airport and Las Vegas’ McCarran International Airport will be completed in 2021. The expanded lounges will feature a suite of amenities for Card Members to enjoy when they resume traveling.
- The Centurion Lounge at LGA will double in size and relocate to a space post-security within the airport’s brand-new, state-of-the-art Terminal B. The new lounge will feature a family room, additional workspaces, private telephone rooms, and views of the New York City skyline.
- The footprint of the first-ever Centurion Lounge, opened at LAS in 2013, will be expanded from nearly 9,000 square feet to over 13,400 square feet. The newly designed lounge will feature additional multi-purpose areas, new private telephone rooms, newly designed reception and workspace areas and more.
American Express is also working towards opening its newest lounge locations later this year in New York’s John F. Kennedy Airport, London’s Heathrow Airport and Denver International Airport.
Creating a Healthy and Safe Environment with The Centurion Lounge Commitment:
While our Centurion Lounges continue to be closed due to COVID-19, American Express is introducing The Centurion Lounge Commitment to further support the health and safety of Card Members and colleagues when the lounges reopen. According to the Amex Trendex*, a trend report from American Express, nearly 2 in 3 consumers say either health and safety policies and procedures (39%) or flexibility (25%) is most important as they look to book future travel.
Card Members will experience new health and safety practices such as socially distanced seating, reduced capacity, increased cleaning frequency, requirements to wear a face covering when entering the lounge, served food instead of buffets, and more. For a contactless check-in experience, Card Members can download the American Express® App and use the Mobile Check-in Feature. These practices will be re-evaluated on an ongoing basis to take into account Card Members’ needs and the requirements of state and local governments and health authorities. Learn more here: thecenturionlounge.com/reopening.
While some may not be ready to travel today, the Amex Trendex* found over half (56%) of consumers who typically travel domestically anticipate feeling comfortable traveling to a domestic destination within six months. American Express is evaluating when to reopen its Centurion Lounge locations based on several factors, including local COVID-19 case prevalence, and will be taking a phased approach, location by location. The company expects to reopen the Centurion Lounges at Seattle-Tacoma airport and Philadelphia International airport on October 5, 2020, with more locations to follow.
*Amex Trendex
Methodology:
This online poll was conducted by Morning Consult poll between August 18-20, 2020 among a national sample of 2,000 general population travelers with a household income of at least $70K, and defined as adults (18+) who traveled by air at least once in 2019. Results from the survey have a margin of error of plus or minus 2 percentage points.
ABOUT AMERICAN EXPRESS
American Express is a globally integrated payments company, providing customers with access to products, insights and experiences that enrich lives and build business success. Learn more at americanexpress.com and connect with us on facebook.com/americanexpress, instagram.com/americanexpress, linkedin.com/company/american-express, twitter.com/americanexpress, and youtube.com/americanexpress.
Key links to products, services and corporate responsibility information: charge and credit cards, business credit cards, travel services, gift cards, prepaid cards, merchant services, Accertify, InAuth, corporate card, business travel, and corporate responsibility.
ABOUT THE CENTURION LOUNGE
The Centurion Lounge is the signature lounge program within the broader American Express Global Lounge Collection, which includes access to American Express Centurion Lounges, international American Express lounges, Delta Sky Club® for Card Members flying on Delta, Priority PassTM Select Lounges upon enrollment, Airspace Lounges, MAG U.S. Escape Lounges and Plaza Premium Lounges--a total of more than 1,300 lounges across 140 countries and counting.
Access to The Centurion Lounge is complementary and exclusive for Platinum Card Members, Centurion Members and Delta SkyMiles® Reserve Card Members. Platinum Card Members may enter with up to two travel companions at no additional charge. Centurion Members may enter with their immediate family or up to two travel companions. Platinum Card and Centurion Members may purchase access to The Centurion Lounge for additional guests for $50 each guest. Delta SkyMiles® Reserve Card Members may bring up to two guests at a per-visit rate of $50 per person, per location.
Location: Global
View source version on businesswire.com: https://www.businesswire.com/news/home/20200916005291/en/
Contact information
AMERICAN EXPRESS
Margot Leeds
Margot.Leeds@aexp.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
ESMO 2020: Cabometyx® (cabozantinib) in Combination With Opdivo® (nivolumab) Demonstrates Significant Survival Benefits in Patients With Advanced Renal Cell Carcinoma in Pivotal Phase III CheckMate -9ER Trial19.9.2020 19:30:00 EEST | Press release
Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today announced the first presentation of results from the pivotal Phase III CheckMate -9ER trial, in which Cabometyx® (cabozantinib) in combination with Bristol Myers Squibb’s Opdivo® (nivolumab) demonstrated significant improvements across all efficacy endpoints, including overall survival (OS), in previously untreated advanced renal cell carcinoma (RCC).1 Cabometyx® in combination with Opdivo® reduced the risk of death by 40% versus sunitinib (HR: 0.60 [98.89% Confidence Interval [CI]: 0.40–0.89]; p= 0.0010; median OS not reached in either arm). In patients receiving Cabometyx® in combination with Opdivo®, median progression-free survival (PFS), the trial’s primary endpoint, was doubled compared to those receiving sunitinib alone: 16.6 months versus 8.3 months respectively (Hazard Ratio [HR]: 0.51 [95% CI 0.41–0.64], p < 0.0001). In addition, Cabometyx® in combination with Opdivo® demonstrated a superior objective response rate, wit
Takeda Presents New Data Highlighting Scientific Advancements in Lung Cancer at ESMO Virtual Congress18.9.2020 13:55:00 EEST | Press release
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that the company is presenting data from its lung cancer portfolio at the virtual European Society for Medical Oncology (ESMO) conference. Notably, insights from sub-analyses of the Phase 3 ALTA 1L study reinforce both the compelling evidence of intracranial efficacy with ALUNBRIG® (brigatinib) as a first-line treatment for patients with anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC) as well as associated quality of life (QoL) data. Takeda is also featuring updated 10-month follow-up results from the Phase 1/2 trial of mobocertinib (TAK-788), demonstrating mobocertinib achieved a duration of response (DoR) of more than one year in the trial’s study population of patients with epidermal growth factor receptor (EGFR) Exon20 insertion+ metastatic NSCLC (mNSCLC). “We’re pleased to present our ongoing research in lung cancer at this year’s virtual ESMO congress, including new
Incyte Announces Encouraging Results From Phase 2 Trial of Retifanlimab (INCMGA0012) in Patients With Previously Treated, Advanced Squamous Cell Carcinoma of the Anal Canal18.9.2020 13:00:00 EEST | Press release
Incyte (Nasdaq:INCY) today announced results from its Phase 2 POD1UM-202 trial evaluating retifanlimab, a PD-1 inhibitor, in previously treated patients with advanced squamous cell carcinoma of the anal canal (SCAC) who have progressed following standard platinum-based chemotherapy. The trial enrolled 94 patients, including those with well-controlled human immunodeficiency virus (HIV) infection (10%). Retifanlimab monotherapy resulted in a confirmed objective response rate (ORR) of 14% as determined by independent central review (ICR) using RECIST v1.1. Responses were observed regardless of PD-L1 status, presence of liver metastases, age or HIV+ status. Retifanlimab was generally well-tolerated with a safety profile as expected of a PD-1 inhibitor and no loss of HIV infection control. Key findings from POD1UM-202: N=94 ORR* (95% CI) 13.8% (7.6-22.5) Best OR*, n 1 CR 12 PR 33 SD DCR 48.9% DOR, median (95% CI), months 9.5 (5.6-NE) PFS, median (95% CI), months 2.3 (1.9-3.6) OS, median (95
Sigfox and Cube Infrastructure Managers Announce Major Partnership in IoT Infrastructure18.9.2020 10:30:00 EEST | Press release
Sigfox, the global 0G network1 and cloud provider for industrial data, is proud to announce a new strategic alliance with Cube Infrastructure Managers (Cube), through the sale of its German 0G network to Cube. Sigfox has grown its 0G IoT services by rolling out 0G networks across 72 countries and regions, which was largely achieved with partners called Sigfox Operators. These operators are the owners of the 0G networks, which they operate as exclusive connectivity providers of Sigfox IoT services, offering worldwide connectivity to customers. The sale of the German network to Cube will allow Sigfox to finance its continued innovation efforts in data value extraction and improvements in cloud algorithms to reduce energy consumption and allow the implementation of even more cost-effective devices and sensors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200918005116/en/ Cube Infrastructure Managers, the European infrastructu
Sensorion successfully raises approximately €31 (US$ 36.5) million in an oversubscribed private placement to US and European investors18.9.2020 09:00:00 EEST | Press release
Regulatory News: Not for release, publication or distribution, directly or indirectly, in or into the United States, Canada, Australia or Japan. This press release is not intended as an offer and is for informational purpose only Sensorion (Paris:ALSEN) (FR0012596468 – ALSEN – the “Company”) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders announces today the success of its previously announced capital increase. The Company has placed 18,236,000 new ordinary shares with a nominal value of €0.10 each (the “New Shares”), for total gross proceeds of approximately € 31 million by means of an accelerated bookbuild offering to the benefit of categories of persons (the “Reserved Offering”). The issue price of the New Shares is €1.70 per share, representing a 3.5% discount to the weighted average share price on the day preceding the date on which the issuance price
ESMO 2020: Phase II CLARINET FORTE Results Show Increasing Dose Frequencies of Somatuline® Autogel® (lanreotide) Allows Patients with NETs to Delay Treatment Escalation by up to 8.3 Months18.9.2020 08:00:00 EEST | Press release
Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today announced the release of first efficacy and safety data from the CLARINET FORTE study, with the abstract to be presented as a mini-oral presentation at the 2020 European Society for Medical Oncology (ESMO) Congress, taking place virtually from 19-21 September 2020. The prospective single-arm, open-label, exploratory, international Phase II study investigated the efficacy and safety of increasing the dose frequency of Somatuline® Autogel ® (lanreotide) in patients with pancreatic or midgut NETs with centrally-assessed progression within the last two years while on a standard lanreotide regimen for ≥24 weeks. An extension of progression-free survival (PFS) rates and encouraging disease-control rates (DCR) were recorded in both tumor types, with no new safety signals. “These results support a clinically meaningful benefit to a population of patients with high unmet medical need by potentially delaying escalation to more toxic treatm
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom